The Danish pharmaceutical giant Novo Nordisk is making a billion-dollar investment in the USA.
The company is investing 4.1 billion dollars, equivalent to over 43 billion Swedish kronor, in its facility in Clayton in the American state of North Carolina.
The idea behind the investment is to double the capacity at the facility.
The reason is the increasing demand for diabetes and obesity medicines Ozempic and Wegovy, which the company is behind.
